Recombinant Humanized Monoclonal Antibody Mil62
B-cell Lymphoma Recurrent
Beijing InnoCare Pharma Tech Co., Ltd.monoclonal_antibodyPhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 89/ 100
Competitive context
317 Active assets in the B-cell Lymphoma Recurrent cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINDESINE Children's Cancer Group, China | Phase 4 | BBB |
Odronextamab University of Birmingham | Phase 3 | BBB |
cc-5013 Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Cytosin-Arabinosid Children's Cancer Group, China | Phase 4 | BBB |
METHOTREXATE Children's Cancer Group, China | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Recombinant Humanized Monoclonal Antibody Mil62 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →